Dubermatinib Uses, Dosage, Side Effects and more

Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).

Trade Name Dubermatinib
Generic Dubermatinib
Dubermatinib Other Names Dubermatinib
Type
Formula C24H30ClN7O2S
Weight Average: 516.06
Monoisotopic: 515.1870221
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share